166 related articles for article (PubMed ID: 30539877)
1. Fatal interstitial lung disease associated with AZD9291.
Deng SM; Huang JA; Chen YB
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1227-S1229. PubMed ID: 30539877
[TBL] [Abstract][Full Text] [Related]
2. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
Jänne PA; Yang JC; Kim DW; Planchard D; Ohe Y; Ramalingam SS; Ahn MJ; Kim SW; Su WC; Horn L; Haggstrom D; Felip E; Kim JH; Frewer P; Cantarini M; Brown KH; Dickinson PA; Ghiorghiu S; Ranson M
N Engl J Med; 2015 Apr; 372(18):1689-99. PubMed ID: 25923549
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
Kodama H; Wakuda K; Yabe M; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Ono A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi T
Invest New Drugs; 2021 Apr; 39(2):571-577. PubMed ID: 32955628
[TBL] [Abstract][Full Text] [Related]
4. Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.
Lin G; Liu Y; Li H; Chen S; Guo Y
Clin Lung Cancer; 2021 Mar; 22(2):e157-e159. PubMed ID: 33158763
[No Abstract] [Full Text] [Related]
5. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease.
Kawase S; Hattori N; Ishikawa N; Horimasu Y; Fujitaka K; Furonaka O; Isobe T; Miyoshi S; Hamada H; Yamane T; Yokoyama A; Kohno N
Respir Res; 2011 Jul; 12(1):97. PubMed ID: 21791074
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study.
Nasu S; Suzuki H; Shiroyama T; Tanaka A; Samejima Y; Kanai T; Noda Y; Morishita N; Okamoto N; Hirashima T
Invest New Drugs; 2020 Dec; 38(6):1915-1920. PubMed ID: 32542461
[TBL] [Abstract][Full Text] [Related]
7. Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.
Ohmori T; Yamaoka T; Ando K; Kusumoto S; Kishino Y; Manabe R; Sagara H
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466795
[TBL] [Abstract][Full Text] [Related]
8. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
[TBL] [Abstract][Full Text] [Related]
9. Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation.
Kawamura T; Kenmotsu H; Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Endo M; Takahashi T
Invest New Drugs; 2020 Feb; 38(1):194-201. PubMed ID: 31183631
[TBL] [Abstract][Full Text] [Related]
10. Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer.
Nishima S; Miyanaga A; Saito S; Yuasa M; Takahashi S; Kashiwada T; Sugano T; Noro R; Minegishi Y; Terasaki Y; Saito Y; Kubota K; Seike M; Gemma A
Intern Med; 2021 Feb; 60(4):591-594. PubMed ID: 32999231
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.
Kim TM; Song A; Kim DW; Kim S; Ahn YO; Keam B; Jeon YK; Lee SH; Chung DH; Heo DS
J Thorac Oncol; 2015 Dec; 10(12):1736-44. PubMed ID: 26473643
[TBL] [Abstract][Full Text] [Related]
12. Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review.
Itano J; Higo H; Ohashi K; Makimoto G; Nishii K; Hotta K; Miyahara N; Maeda Y; Kiura K
Intern Med; 2020 Mar; 59(6):823-828. PubMed ID: 31787696
[TBL] [Abstract][Full Text] [Related]
13. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma.
Verma A; Chopra A; Lee YW; Bharwani LD; Asmat AB; Aneez DB; Akbar FA; Lim AY; Chotirmall SH; Abisheganaden J
Curr Drug Discov Technol; 2016; 13(2):68-76. PubMed ID: 27216707
[TBL] [Abstract][Full Text] [Related]
14. Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody.
Mamesaya N; Kenmotsu H; Katsumata M; Nakajima T; Endo M; Takahashi T
Invest New Drugs; 2017 Feb; 35(1):105-107. PubMed ID: 27599705
[TBL] [Abstract][Full Text] [Related]
15. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
16. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
[TBL] [Abstract][Full Text] [Related]
17. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
18. Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report.
Wang J; Chen J
BMC Cancer; 2019 Feb; 19(1):131. PubMed ID: 30736738
[TBL] [Abstract][Full Text] [Related]
19. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.
Remon J; Planchard D
Future Oncol; 2015 Nov; 11(22):3069-81. PubMed ID: 26450446
[TBL] [Abstract][Full Text] [Related]
20. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
